|Day Low/High||337.29 / 357.64|
|52 Wk Low/High||102.66 / 497.49|
These names are displaying both quantitative and technical deterioration.
CVAC is now working on a 'next generation' COVID-19 vaccine candidate with GlaxoSmithKline.
And I was right, and the cynics were wrong. Here's why that matters more than ever now.
I prefer the bear put spread over the covered equity play due to the decreased risk to principal, despite the capped potential for profit.
Plus, it appears there may be headway on an infrastructure bill that could work for both sides of the aisle.
We've been caught with our pants down, largely because we had no faith in the smartest people in the country.
Debt-free and poised to gain from its COVID-19 vaccine demand, MRNA could inject some life into your investment plan.
The market seems to rejoice from the latest mask utterance out of the CDC, but the action at the Nasdaq should give traders pause.
ARCT's IP is incredibly valuable, and may in fact be invaluable.
The fund is at a key spot technically, and there is real fear that if this spot cracks, what looks like a stretch of rough rapids could become a waterfall.
UPS and FDX are both in serious rally mode, yet in very different places in terms of technical development.
Perhaps the most interesting result of an inflationary but not frightening CPI was visible in U.S. Treasury security markets.
You never want to be caught in a counter trend rally.
Don't forget, this is a very large company with a lot more than the vaccine going on.
I would argue that the pandemic has lasted just long enough to wipe out the little guy and let the bigger guys have the run of the joint.
My COVID vaccine eligibility actually began about a week before my symptoms began.
A buy-write makes sense here, but the premiums are tight, so I'd rather do a buy-ratio spread.
Outside of the pro sports world, it seems like amateur hour with regard to protocols.
Here's my view on this space and where the money is to be made.
Let's look back at how the market reacted to COVID-19 one year ago, and the lessons we can learn.
COVID numbers stopped improving a while ago, even with ever-improving rates of vaccination. Just what is going on here?
Let's set out the case for stocks -- and which kind -- and whether you might want to pay down other debt first.
Plus, the efficacy rate of the still-pending Novavax Covid-19 vaccine against variants of the virus give reason for pause.
How does this all end? I don't know that it does end.
Should we care about Australia's central bank taking overtly aggressive action to reign in the long end of their yield curve? Yes, we should.
The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.
I want you to think about how quickly the long end of the U.S. Treasury curve is moving.
A year ago the stock market was flying high, only to plummet with the spread of a deadly, mysterious virus; this is the story of how it found a bottom.
As an early vaccinator I can tell you that you can make money from these strange things provided you do them before everybody gets the jab.